Subscribe
shutterstock_1960556293_molly_woodward
Molly Woodward / Shutterstock.com
16 November 2021AmericasMuireann Bolger

Pfizer’s Wyeth sues Novartis’ Sandoz over breast cancer drug patent

Pfizer subsidiary Wyeth Pharmaceuticals has filed a suit jointly with Puma Biotechnology against Sandoz over a patent related to breast cancer drug, Nerlynx (neratinib).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
NextCure targeted in cancer drug trade secrets suit
16 December 2021   Public biopharmaceutical company NextCure has been accused of misappropriating trade secrets in order to create a direct competitor to a biotech’s cancer immunotherapy technology.
Americas
Amgen, Pfizer settle patent suit over cancer treatment
7 September 2021   Amgen has settled its dispute with Pfizer subsidiary Hospira, which it had accused of infringing a patent covering its blockbuster cancer drug treatment Neupogen.
Americas
Actavis and Pfizer settle Celebrex litigation
29 April 2014   Actavis has entered into an agreement with Pfizer to settle all outstanding patent litigation related to Pfizer’s arthritis drug Celebrex (celecoxib).


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025

More on this story

Biotechnology
NextCure targeted in cancer drug trade secrets suit
16 December 2021   Public biopharmaceutical company NextCure has been accused of misappropriating trade secrets in order to create a direct competitor to a biotech’s cancer immunotherapy technology.
Americas
Amgen, Pfizer settle patent suit over cancer treatment
7 September 2021   Amgen has settled its dispute with Pfizer subsidiary Hospira, which it had accused of infringing a patent covering its blockbuster cancer drug treatment Neupogen.
Americas
Actavis and Pfizer settle Celebrex litigation
29 April 2014   Actavis has entered into an agreement with Pfizer to settle all outstanding patent litigation related to Pfizer’s arthritis drug Celebrex (celecoxib).

More on this story

Biotechnology
NextCure targeted in cancer drug trade secrets suit
16 December 2021   Public biopharmaceutical company NextCure has been accused of misappropriating trade secrets in order to create a direct competitor to a biotech’s cancer immunotherapy technology.
Americas
Amgen, Pfizer settle patent suit over cancer treatment
7 September 2021   Amgen has settled its dispute with Pfizer subsidiary Hospira, which it had accused of infringing a patent covering its blockbuster cancer drug treatment Neupogen.
Americas
Actavis and Pfizer settle Celebrex litigation
29 April 2014   Actavis has entered into an agreement with Pfizer to settle all outstanding patent litigation related to Pfizer’s arthritis drug Celebrex (celecoxib).

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims